Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPGJ602 with Chemotherapy in Metastatic Colorectal Cancer
NCT04466254Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CPGJ602 in metastatic colorectal cancer (mCRC), sponsored by 3S Guojian Pharmaceutical. Status: unknown.
02
Drugs
CPGJ602
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04466254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466254.